Rituximab biosimilar - Dr Reddy's Laboratories

Drug Profile

Rituximab biosimilar - Dr Reddy's Laboratories

Alternative Names: DRL-rituximab; DRL_RI; REDDITUX; Reditux; Tidecron

Latest Information Update: 16 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dr Reddys Laboratories
  • Developer CinnaGen; Dr Reddys Laboratories
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Non-Hodgkin's lymphoma; Rheumatoid arthritis
  • Registered Chronic lymphocytic leukaemia
  • Phase II Diffuse large B cell lymphoma

Most Recent Events

  • 09 Mar 2018 TRPharm intends to launch rituximab biosimilar for treatment of Non-Hodgkin's lymphoma in Turkey
  • 30 Jan 2018 Preregistration for Chronic lymphocytic leukaemia in Turkey (IV) before January 2018
  • 30 Jan 2018 Registered for Chronic lymphocytic leukaemia in Turkey (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top